You are here

  • Home
  • Archive
  • Volume 72, Issue Suppl 3
  • SAT0110 Efficacy and Safety of Pateclizumab (Anti-Lymphotoxin-Alpha) in Dmard-Ir Patients: Results of a Randomized, Double-Blind, Placebo-Controlled Head-To-Head Phase 2 Study with Adalimumab

Citation Tools

Article menu
Download PDFPDF
Scientific Abstracts
Rheumatoid arthritis - other biologictreatment
SAT0110 Efficacy and Safety of Pateclizumab (Anti-Lymphotoxin-Alpha) in Dmard-Ir Patients: Results of a Randomized, Double-Blind, Placebo-Controlled Head-To-Head Phase 2 Study with Adalimumab

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Kennedy W, Horn P, Su Z, et al
SAT0110 Efficacy and Safety of Pateclizumab (Anti-Lymphotoxin-Alpha) in Dmard-Ir Patients: Results of a Randomized, Double-Blind, Placebo-Controlled Head-To-Head Phase 2 Study with Adalimumab
Annals of the Rheumatic Diseases 2013;72:A617-A618.